What Next for INMED PHARMACEUTICALS INC ORDINARY SHAR (OTCMKTS:IMLFF) Stock After Increase in Shorted Shares?

The stock of INMED PHARMACEUTICALS INC ORDINARY SHAR (OTCMKTS:IMLFF) registered an increase of 13.75% in short interest. IMLFF’s total short interest was 1.23 million shares in September as published by FINRA. Its up 13.75% from 1.08 million shares, reported previously. With 398,500 shares average volume, it will take short sellers 3 days to cover their IMLFF’s short positions.

The stock decreased 1.75% or $0.0048 during the last trading session, reaching $0.27. About 223,183 shares traded. InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, engages in the research and development of novel and cannabinoid therapies in Canada. The company has market cap of $45.20 million. The companyÂ’s products under pre-clinical development stage include INM-750 for the treatment of epidermolysis bullosa; and INM-085 for the treatment of glaucoma. It currently has negative earnings. It is also developing various drugs for diseases, such as ocular, pain and inflammation, dermatology, central nervous system, metabolic, and respiratory.

More notable recent InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF) news were published by: Seekingalpha.com which released: “Horizons Marijuana Life Sciences Index ETF: 2018 Q2 Update – Seeking Alpha” on July 12, 2018, also Midasletter.com with their article: “InMed Pharmaceuticals Inc (TSE:IN) Developing Treatment for Epidermolysis Bullosa – Midas Letter” published on January 16, 2019, Seekingalpha.com published: “InMed Pharmaceuticals (IMLFF) Presents At Biotech Showcase 2019 – Slideshow – Seeking Alpha” on January 09, 2019. More interesting news about InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF) were released by: Seekingalpha.com and their article: “Aphria May Get A Partner And A Pop Higher In The Stock – Seeking Alpha” published on October 22, 2018 as well as Seekingalpha.com‘s news article titled: “InMed Pharma pivots to single-agent cannabinoid for rare skin disorder; shares up 2% – Seeking Alpha” with publication date: March 13, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.